GCTK vs NXTC vs DXCM vs FATE vs ABT

For growth investors, DexCom, Inc.

(DXCM) is the stronger pick with 15. 6% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). GlucoTrack, Inc. (GCTK) offers the better valuation at 0. 0x trailing P/E, making it the more compelling value choice. Analysts rate DexCom, Inc. (DXCM) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GlucoTrack, Inc.

(GCTK) is the cheapest at 0. 0x versus DexCom, Inc. at 29. 1x. On forward P/E, Abbott Laboratories is actually cheaper at 15. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Abbott Laboratories wins at 0. 53x versus DexCom, Inc. 's 2. 34x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Abbott Laboratories (ABT) delivered a total return of -17.

9%, compared to -100. 0% for GlucoTrack, Inc. (GCTK). Over 10 years, the gap is even starker: DXCM returned +290. 2% versus GCTK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

25β versus Fate Therapeutics, Inc. 's 2. 17β — meaning FATE is approximately 775% more volatile than ABT relative to the S&P 500. On balance sheet safety, NextCure, Inc. (NXTC) carries a lower debt/equity ratio of 12% versus 51% for DexCom, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), DexCom, Inc.

(DXCM) is pulling ahead at 15. 6% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: GlucoTrack, Inc. grew EPS 258. 6% year-over-year, compared to 17. 7% for NextCure, Inc.. Over a 3-year CAGR, DXCM leads at 17. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DXCM leads at 19. 6% versus -22. 2% for FATE. At the gross margin level — before operating expenses — DXCM leads at 60. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Abbott Laboratories (ABT) is the more undervalued stock at a PEG of 0. 53x versus DexCom, Inc. 's 2. 34x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Abbott Laboratories (ABT) trades at 15. 9x forward P/E versus 24. 5x for DexCom, Inc. — 8. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FATE: 1525. 5% to $39. 50.

In this comparison, ABT (2.

5% yield) pays a dividend. GCTK, NXTC, DXCM, FATE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

25), 2. 5% yield, +173. 7% 10Y return). Fate Therapeutics, Inc. (FATE) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +173. 7%, FATE: +40. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GCTK is a small-cap deep-value stock; NXTC is a small-cap quality compounder stock; DXCM is a mid-cap high-growth stock; FATE is a small-cap quality compounder stock; ABT is a mid-cap deep-value stock. ABT pays a dividend while GCTK, NXTC, DXCM, FATE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.